<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05009992</url>
  </required_header>
  <id_info>
    <org_study_id>200821</org_study_id>
    <secondary_id>NCI-2021-08386</secondary_id>
    <nct_id>NCT05009992</nct_id>
  </id_info>
  <brief_title>Combination Therapy for the Treatment of Diffuse Midline Gliomas</brief_title>
  <official_title>A Combination Therapy Trial Using an Adaptive Platform Design for Children and Young Adults With Diffuse Midline Gliomas (DMGs) Including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Chad-Tough Defeat DIPG Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mithil Prasad Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Storm the Heavens Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial determines if the combination of ONC201 with different drugs,&#xD;
      panobinostat or paxalisib, is effective for treating patients with diffuse midline gliomas&#xD;
      (DMGs). Despite years of research, little to no progress has been made to improve outcomes&#xD;
      for patients with DMGs, and there are few treatment options. ONC201, panobinostat, and&#xD;
      paxalisib are all enzyme inhibitors that may stop the growth of tumor cells by clocking some&#xD;
      of the enzymes needed for cell growth. This phase II trial assesses different combinations of&#xD;
      these drugs for the treatment of DMGs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:&#xD;
&#xD;
      Participants will be randomized at study entry to one of the six study arms and subsequently&#xD;
      will be included in one to three phases, and one of 3 cohorts depending on their stage of&#xD;
      disease and prior treatment.&#xD;
&#xD;
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To assess efficacy of combination therapy with ONC201 (ONC201) and novel agent in&#xD;
      participants with DMG based on median progression-free survival at 6 months (PFS6) (Cohorts 1&#xD;
      and 2).&#xD;
&#xD;
      II. To assess efficacy of combination therapy with ONC201 and novel agent in participants&#xD;
      with recurrent DMG based on overall survival at 7 months (OS7) (Cohort 3).&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. To confirm blood brain barrier (BBB) penetration of ONC201 in DMGs by measuring the&#xD;
      concentration of ONC201 in tumor tissue (All cohorts; target validation phase).&#xD;
&#xD;
      II. To confirm BBB penetration of novel agents in DMGs by measuring the concentration of drug&#xD;
      (or metabolite) in tumor tissue (All cohorts; target validation phase).&#xD;
&#xD;
      III. To assess changes in immune cell infiltration in DMG tumor tissue after 1 or 2 doses of&#xD;
      ONC201 (All cohorts; target validation phase).&#xD;
&#xD;
      IV. To assess correlation of intratumoral concentration of ONC201 with clinical outcome (All&#xD;
      cohorts; target validation phase).&#xD;
&#xD;
      V. To assess correlation of intratumoral drug concentration of novel agents with clinical&#xD;
      outcome. (All cohorts; target validation phase).&#xD;
&#xD;
      VI. To assess if intratumoral ONC201 concentrations differ in irradiated versus nonirradiated&#xD;
      tumor tissue. (All cohorts; target validation phase).&#xD;
&#xD;
      VII. To assess if intratumoral concentrations of novel agents differ in irradiated versus&#xD;
      nonirradiated tumor tissue. (All cohorts; target validation phase).&#xD;
&#xD;
      VIII. To assess tumor tissue biomarkers in the context of clinical outcome, such as PFS6&#xD;
      and/or OS12. (All cohorts; target validation phase).&#xD;
&#xD;
      IX. To assess efficacy of combination therapy ONC201 and novel agent based on overall&#xD;
      survival at 12 months (OS12). (All cohorts; maintenance combinations).&#xD;
&#xD;
      X. To assess toxicity of combination therapy ONC201 and novel agents. (All cohorts;&#xD;
      maintenance combinations).&#xD;
&#xD;
      XI. To assess the toxicity of weekly ONC201 in combination with up-front radiation therapy.&#xD;
      (Cohort 1; radiation therapy phase).&#xD;
&#xD;
      XII. To assess the toxicity of twice weekly ONC201 in combination with up-front radiation&#xD;
      therapy. (Cohort 1; radiation therapy phase).&#xD;
&#xD;
      XIII. To assess the toxicity of novel agents in combination with up-front radiation therapy.&#xD;
      (Cohort 1; radiation therapy phase).&#xD;
&#xD;
      XIV. To assess the toxicity of weekly ONC201 in combination with re-irradiation after&#xD;
      progression. (Cohort 3).&#xD;
&#xD;
      XV. To assess the toxicity of twice weekly ONC201 in combination with re-irradiation therapy&#xD;
      after progression. (Cohort 3).&#xD;
&#xD;
      XVI. To assess the toxicity of novel agents in combination with re-irradiation after&#xD;
      progression. (Cohort 3).&#xD;
&#xD;
      XVII. To assess the toxicity of ONC201 in combination with novel agents in participants after&#xD;
      re-irradiation after progression. (Cohort 3).&#xD;
&#xD;
      XVIII. To assess cerebrospinal fluid (CSF) biomarkers in the context of clinical outcome,&#xD;
      such as PFS6 and/or OS12. (All cohorts/phases).&#xD;
&#xD;
      XIX. To assess levels of circulating tumor deoxyribonucleic acid (ctDNA) in the context of&#xD;
      imaging response criteria and clinical outcome, such as PFS6 and/or OS12. (All&#xD;
      cohorts/phases).&#xD;
&#xD;
      XX. To assess single cell ribonucleic acid (RNA) sequencing in the context of clinical&#xD;
      outcome, such as PFS6 and/or OS12. (All cohorts/phases).&#xD;
&#xD;
      XXI. To assess Health-Related Quality of Life (HRQOL) and cognitive measures. (All&#xD;
      cohorts/phases).&#xD;
&#xD;
      XXII. To assess patient and/or proxy satisfaction with study participation via&#xD;
      patient-reported outcome (PRO) measures. (All cohorts/phases).&#xD;
&#xD;
      COHORT DESCRIPTIONS:&#xD;
&#xD;
      COHORTS 1A &amp; 2A ( Target Validation cohorts); Includes newly diagnosed participants that have&#xD;
      not yet undergone tumor tissue collection. Cohort 1A will include participants with DMG who&#xD;
      have not yet completed radiation therapy and Cohort 2A will include participants with DMG who&#xD;
      have completed radiation therapy.&#xD;
&#xD;
      COHORTS 1B &amp; 2B: Includes newly-diagnosed participants who have already undergone tumor&#xD;
      tissue collection. Cohort 1B will include participants with DMG who have not yet completed&#xD;
      radiation therapy and Cohort 2B will include participants with DMG who have completed&#xD;
      radiation therapy.&#xD;
&#xD;
      COHORTS 3A &amp; 3B: Includes participants with progressive DMG. Cohort 3A will include&#xD;
      participants planned for standard of care (SOC) tumor tissue collection. Cohort 3B will&#xD;
      include participants not planned for SOC tumor tissue collection. The nomenclature will&#xD;
      delineate participants previously enrolled in Cohorts 1 or 2.&#xD;
&#xD;
      TREATMENT ARM DESCRIPTIONS:&#xD;
&#xD;
      ARM 1: During the trial validation phase, patients without prior biopsy receive ONC201 orally&#xD;
      (PO) on day -1 prior to stand of care biopsy. During the radiation/re-irradiation phase,&#xD;
      patients without prior radiation therapy or have disease progression after radiation therapy&#xD;
      undergo weekly radiation therapy and receive ONC201 PO weekly during radiation therapy.&#xD;
      During the maintenance phase, patients receive ONC201 PO weekly and panobinostat PO every&#xD;
      other day, 3 times a week during weeks 1 and 3. Cycles repeat every 28 days (4 weeks) in the&#xD;
      absence adverse events or unacceptable toxicity.&#xD;
&#xD;
      ARM 2: During the trial validation phase, patients without prior biopsy receive ONC201 PO on&#xD;
      day -1 prior to standard of care biopsy. During the radiation/re-irradiation phase, patients&#xD;
      without prior radiation therapy or have disease progression after radiation therapy undergo&#xD;
      weekly radiation therapy and receive ONC201 PO weekly during radiation therapy. During the&#xD;
      maintenance phase, patients receive ONC201 PO weekly and paxalisib PO daily (QD). Cycles&#xD;
      repeat every 28 days (4 weeks) in the absence of adverse events of unacceptable toxicity.&#xD;
&#xD;
      ARM 3: During the trial validation phase, patients without prior biopsy receive ONC201 PO on&#xD;
      days -2 and -1 prior to standard of care biopsy. During the radiation/re-irradiation phase,&#xD;
      patients without prior radiation therapy or have disease progression after radiation therapy&#xD;
      undergo weekly radiation therapy and receive ONC201 PO weekly during radiation therapy.&#xD;
      During the maintenance phase, patients receive ONC201 PO weekly and panobinostat every other&#xD;
      day, 3 times a week during weeks 1 and 3. Cycles repeat every 28 days (4 weeks) in the&#xD;
      absence of adverse events of unacceptable toxicity.&#xD;
&#xD;
      ARM 4: During the trial validation phase, patients without prior biopsy receive ONC201 PO on&#xD;
      days -2 and -1 prior to standard of care biopsy. During the radiation/re-irradiation phase,&#xD;
      patients may receive ONC201 PO weekly during radiation therapy. During the maintenance phase,&#xD;
      patients receive ONC201 PO weekly and paxalisib PO QD. Cycles repeat every 28 days (4 weeks)&#xD;
      in the absence of adverse events or unacceptable toxicity.&#xD;
&#xD;
      ARM 5: During the trial validation phase, patients without prior biopsy receive panobinostat&#xD;
      PO on day -7 prior to standard of care biopsy. During the radiation/re-irradiation phase,&#xD;
      patients without prior radiation therapy or have disease progression after radiation therapy&#xD;
      undergo weekly radiation therapy and receive panobinostat PO every other day, 3 times a week,&#xD;
      every other week during radiation therapy. During the maintenance phase, patients receive&#xD;
      ONC201 PO weekly and panobinostat every other day, 3 times a week during weeks 1 and 3.&#xD;
      Cycles repeat every 28 days (4 weeks) in the absence of adverse events or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      ARM 6: During trial validation phase, patients without prior biopsy receive paxalisib PO on&#xD;
      day -1 prior to standard of care biopsy. During the radiation/re-irradiation phase, patients&#xD;
      without prior radiation therapy or have disease progression after radiation therapy undergo&#xD;
      weekly radiation therapy and receive paxalisib PO daily during radiation therapy. During the&#xD;
      maintenance phase, patients receive ONC201 PO weekly and paxalisib PO QD. Cycles repeat every&#xD;
      28 days (4 weeks) in the absence of adverse events of unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patient are followed every 12 months.&#xD;
&#xD;
      Arm 1 &amp; 3 will be open to Cohort 2 initially for safety lead in. Arms 2, 4, 5, and 6 in&#xD;
      Cohort 2 and Arms 1, 3 and 5 in Cohorts 1 and 3 will not open until the recommended phase II&#xD;
      dose (RP2D) for panobinostat is confirmed from the safety lead-in. Once the RP2D for&#xD;
      panobinostat is confirmed, the investigator will open all arms across all cohorts.&#xD;
&#xD;
      If the RP2D (outside of this trial) is declared before full completion our safety lead-in,&#xD;
      the investigator will transition to opening all arms and cohorts immediately and use the&#xD;
      declared RP2D for all panobinostat arms and cohorts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival at 6 months (PFS6) - Cohorts 1A, 1B, 2A, 2B Only</measure>
    <time_frame>6 months after administration of ONC201 in the maintenance phase</time_frame>
    <description>Percentage of participants alive and free from progression at 6 months after the initiation of the combination of the backbone (i.e., ONC201) with a novel agent given in the maintenance phase of therapy. The primary analysis for PFS6 is based on the intention to treat (ITT) population, according to treatment arm assignment. PFS6 is estimated using the Kaplan-Meier method with exact confidence intervals for each cohort and arm. Participants with unknown progression status at 6 months are considered failures (i.e., progressed) for the PFS6 analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival at 7 months (OS7) - Cohort 3A &amp; 3B Only</measure>
    <time_frame>7 months after administration of ONC201 in the maintenance phase</time_frame>
    <description>OS7 is defined as the percentage of participants alive at 7 months after the initiation of the combination of the backbone (i.e., ONC201) with a novel agent given in the maintenance phase of therapy. The primary analysis for OS7 is based on the ITT population, according to treatment arm assignment. OS7 is estimated using the Kaplan-Meier method with exact confidence intervals for each cohort and arm. Participants with unknown survival status at 7 months are considered failures (i.e., dead) for the OS7 analysis.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Diffuse Intrinsic Pontine Glioma</condition>
  <condition>Diffuse Midline Glioma, H3 K27M-Mutant</condition>
  <condition>Recurrent Diffuse Intrinsic Pontine Glioma</condition>
  <condition>Recurrent Diffuse Midline Glioma, H3 K27M-Mutant</condition>
  <condition>Recurrent WHO Grade III Glioma</condition>
  <condition>WHO Grade III Glioma</condition>
  <arm_group>
    <arm_group_label>ARM 1: ONC201 (Day -1), Radiation+ONC201, Panobinostat+ONC201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients may receive a safety lead in of ONC201. During the trial validation phase, patients without prior biopsy receive ONC201 orally (PO) on day -1 prior to stand of care biopsy. During the radiation/re-irradiation phase, patients without prior radiation therapy or have disease progression after radiation therapy undergo weekly radiation therapy and receive ONC201 orally (PO) weekly during radiation therapy. During the maintenance phase, patients receive ONC201 PO weekly and panobinostat PO every other day, 3 times a week during weeks 1 and 3. Cycles repeat every 28 days (4 weeks) in the absence adverse events or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM 2: ONC201 (Day -1), Radiation+ONC201, Paxalisib+ONC201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients may receive a safety lead in of ONC201. During the trial validation phase, patients without prior biopsy receive ONC201 PO on day -1 prior to standard of care biopsy. During the radiation/re-irradiation phase, patients without prior radiation therapy or have disease progression after radiation therapy undergo weekly radiation therapy and receive ONC201 PO weekly during radiation therapy. During the maintenance phase, patients receive ONC201 PO weekly and paxalisib PO daily (QD). Cycles repeat every 28 days (4 weeks) in the absence of adverse events of unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM 3: ONC201 (Day -1,-2), Radiation+ONC201, Panobinostat+ONC201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients may receive a safety lead in of ONC201. Patients will receive a safety lead in of ONC201. During the trial validation phase, patients without prior biopsy receive ONC201 PO on days -2 and -1 prior to standard of care biopsy. During the radiation/re-irradiation phase, patients without prior radiation therapy or have disease progression after radiation therapy undergo weekly radiation therapy and receive ONC201 PO weekly during radiation therapy. During the maintenance phase, patients receive ONC201 PO weekly and panobinostat every other day, 3 times a week during weeks 1 and 3. Cycles repeat every 28 days (4 weeks) in the absence of adverse events of unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM 4: ONC201 (Day -1,-2), Radiation+ONC201, Paxalisib+ONC201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients may receive a safety lead in of ONC201. During the trial validation phase, patients without prior biopsy receive ONC201 PO on days -2 and -1 prior to standard of care biopsy. During the radiation/re-irradiation phase, patients may receive ONC201 PO weekly during radiation therapy. During the maintenance phase, patients receive ONC201 PO weekly and paxalisib PO QD. Cycles repeat every 28 days (4 weeks) in the absence of adverse events or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM 5: Panobinostat (Day -7), Radiation+Panobinostat, Panobinostat+ONC201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients may receive a safety lead in of ONC201. During the trial validation phase, patients without prior biopsy receive panobinostat PO on day -7 prior to standard of care biopsy. During the radiation/re-irradiation phase, patients without prior radiation therapy or have disease progression after radiation therapy undergo weekly radiation therapy and receive panobinostat PO every other day, 3 times a week, every other week during radiation therapy. During the maintenance phase, patients receive ONC201 PO weekly and panobinostat every other day, 3 times a week during weeks 1 and 3. Cycles repeat every 28 days (4 weeks) in the absence of adverse events or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM 6: Paxalisib (Day -1), Radiation+Paxalisib , Paxalisib+ONC201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients may receive a safety lead in of ONC201. During trial validation phase, patients without prior biopsy receive paxalisib PO on day -1 prior to standard of care biopsy. During the radiation/re-irradiation phase, patients without prior radiation therapy or have disease progression after radiation therapy undergo weekly radiation therapy and receive paxalisib PO daily during radiation therapy. During the maintenance phase, patients receive ONC201 PO weekly and paxalisib PO QD. Cycles repeat every 28 days (4 weeks) in the absence of adverse events of unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONC201</intervention_name>
    <description>Given orally (PO)</description>
    <arm_group_label>ARM 1: ONC201 (Day -1), Radiation+ONC201, Panobinostat+ONC201</arm_group_label>
    <arm_group_label>ARM 2: ONC201 (Day -1), Radiation+ONC201, Paxalisib+ONC201</arm_group_label>
    <arm_group_label>ARM 3: ONC201 (Day -1,-2), Radiation+ONC201, Panobinostat+ONC201</arm_group_label>
    <arm_group_label>ARM 4: ONC201 (Day -1,-2), Radiation+ONC201, Paxalisib+ONC201</arm_group_label>
    <arm_group_label>ARM 5: Panobinostat (Day -7), Radiation+Panobinostat, Panobinostat+ONC201</arm_group_label>
    <arm_group_label>ARM 6: Paxalisib (Day -1), Radiation+Paxalisib , Paxalisib+ONC201</arm_group_label>
    <other_name>TIC10</other_name>
    <other_name>Antagonist of dopamine receptor D2 (DRD2) and caseinolytic protease proteolytic subunit (ClpP)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Undergo radiation therapy</description>
    <arm_group_label>ARM 1: ONC201 (Day -1), Radiation+ONC201, Panobinostat+ONC201</arm_group_label>
    <arm_group_label>ARM 2: ONC201 (Day -1), Radiation+ONC201, Paxalisib+ONC201</arm_group_label>
    <arm_group_label>ARM 3: ONC201 (Day -1,-2), Radiation+ONC201, Panobinostat+ONC201</arm_group_label>
    <arm_group_label>ARM 4: ONC201 (Day -1,-2), Radiation+ONC201, Paxalisib+ONC201</arm_group_label>
    <arm_group_label>ARM 5: Panobinostat (Day -7), Radiation+Panobinostat, Panobinostat+ONC201</arm_group_label>
    <arm_group_label>ARM 6: Paxalisib (Day -1), Radiation+Paxalisib , Paxalisib+ONC201</arm_group_label>
    <other_name>Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panobinostat</intervention_name>
    <description>Given PO</description>
    <arm_group_label>ARM 1: ONC201 (Day -1), Radiation+ONC201, Panobinostat+ONC201</arm_group_label>
    <arm_group_label>ARM 3: ONC201 (Day -1,-2), Radiation+ONC201, Panobinostat+ONC201</arm_group_label>
    <arm_group_label>ARM 5: Panobinostat (Day -7), Radiation+Panobinostat, Panobinostat+ONC201</arm_group_label>
    <other_name>HDAC inhibitor</other_name>
    <other_name>LBH589</other_name>
    <other_name>Faridak</other_name>
    <other_name>(2E)-N-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino)methyl)phenyl)prop-2-enamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paxalisib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>ARM 2: ONC201 (Day -1), Radiation+ONC201, Paxalisib+ONC201</arm_group_label>
    <arm_group_label>ARM 4: ONC201 (Day -1,-2), Radiation+ONC201, Paxalisib+ONC201</arm_group_label>
    <arm_group_label>ARM 6: Paxalisib (Day -1), Radiation+Paxalisib , Paxalisib+ONC201</arm_group_label>
    <other_name>Inhibitor of the PI3K/AKT/mTOR pathway</other_name>
    <other_name>GDC-0084</other_name>
    <other_name>GDC0084</other_name>
    <other_name>PI3K Inhibitor GDC-0084</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  â€¢ COHORT 1A AND 1B: New diagnosis of DMG with imaging and/or pathology consistent with&#xD;
             a DMG, including spinal cord tumors. In cohort 1B, previous tumor tissue confirmation&#xD;
             of DMG is mandatory and pathology must be consistent with a DMG including diffuse&#xD;
             midline glioma H3K27M mutant; World Health Organization (WHO) grade III and IV H3&#xD;
             wildtype gliomas.&#xD;
&#xD;
               -  COHORT 2A AND 2B: Diagnosis of DMG with imaging and/or pathology consistent with&#xD;
                  a DMG, including spinal cord tumors, who have complete standard-of-care radiation&#xD;
                  therapy. In cohort 2B, previous tumor tissue confirmation of DMG is mandatory and&#xD;
                  pathology must be consistent with a DMG including diffuse midline glioma H3K27M&#xD;
                  mutant; WHO grade III and IV H3 wildtype gliomas.&#xD;
&#xD;
               -  COHORT 2A AND 2B: Participants must be within 4-14 weeks of completion of&#xD;
                  radiation.&#xD;
&#xD;
               -  COHORT 3A AND 3B: Diagnosis of recurrent DMG with imaging and/or pathology&#xD;
                  consistent with a DMG, including spinal cord tumors, who have complete&#xD;
                  standard-of-care radiation therapy. In cohort 3B, previous tumor tissue&#xD;
                  confirmation of DMG is mandatory and pathology must be consistent with a DMG&#xD;
                  including diffuse midline glioma H3K27M mutant; WHO grade III and IV H3 wildtype&#xD;
                  gliomas.&#xD;
&#xD;
               -  COHORT 3A AND 3B: Participants must have evidence of progression and not have&#xD;
                  received any treatment for this progression and have not previously received&#xD;
                  re-irradiation.&#xD;
&#xD;
               -  Age 2 to 39 years&#xD;
&#xD;
               -  Participants must have recovered from all acute side effects of prior therapy&#xD;
&#xD;
               -  Participant body weight must be above the minimum necessary for the participant&#xD;
                  to receive ONC201 (at least 10 kg)&#xD;
&#xD;
               -  From the projected start of scheduled study treatment, the following time periods&#xD;
                  must have elapsed: At least 7 days after last dose of a biologic agent or beyond&#xD;
                  time during which adverse events are known to occur for a biologic agent, 5&#xD;
                  half-lives from any investigational agent, 4 weeks from cytotoxic therapy (except&#xD;
                  23 days for temozolomide and 6 weeks from nitrosoureas), 6 weeks from antibodies,&#xD;
                  or 4 weeks (or 5 half-lives, whichever is shorter) from other anti-tumor&#xD;
                  therapies.&#xD;
&#xD;
                    -  For participants who have received radiotherapy, participants in cohort 2&#xD;
                       must be between 4 and 14 weeks from the completion of local up-front&#xD;
                       radiotherapy.&#xD;
&#xD;
                    -  The use of bevacizumab to control radiation therapy-induced edema is&#xD;
                       allowed.&#xD;
&#xD;
                    -  Prior use of temozolomide during radiation at maximum of the standard&#xD;
                       pediatric dosing (defined as 90 mg/m2 /dose continuously during radiation&#xD;
                       therapy for 42 days) or dexamethasone is allowed.&#xD;
&#xD;
               -  Corticosteroids: Participants who are receiving dexamethasone must be on a stable&#xD;
                  or decreasing dose for at least 3 days prior to baseline magnetic resonance&#xD;
                  imaging (MRI) scan.&#xD;
&#xD;
               -  Peripheral absolute neutrophil count (ANC) &gt;= 1000/mm^3 (1.0g/l) AND&#xD;
&#xD;
               -  Platelet count &gt;= 100,000/mm^3 (100x10^9/l) (transfusion independent, defined as&#xD;
                  not receiving platelet transfusions for at least 7 days prior to enrollment).&#xD;
&#xD;
               -  Creatinine clearance or radioisotope glomerular filtration rate (GFR) &gt;=&#xD;
                  70mL/min/1.73 m^2 OR&#xD;
&#xD;
               -  A serum creatinine within the normal limits for age&#xD;
&#xD;
               -  Bilirubin (sum of conjugated + unconjugated) =&lt; 1.5 x upper limit of normal (ULN)&#xD;
                  for age AND&#xD;
&#xD;
               -  Serum glutamate pyruvate transaminase (SGPT)(alanine aminotransferase (ALT)) =&lt; 2&#xD;
                  x ULN AND&#xD;
&#xD;
               -  Serum albumin &gt;= 2 g/dL&#xD;
&#xD;
               -  Serum lipase =&lt; ULN at baseline&#xD;
&#xD;
               -  No evidence of dyspnea at rest, no exercise intolerance due to pulmonary&#xD;
                  insufficiency, and a pulse oximetry of &gt; 92% while breathing room air.&#xD;
&#xD;
               -  Diarrhea &lt; grade 2 by Common Terminology Criteria for Adverse Events (CTCAE)&#xD;
                  version (v) 5.0&#xD;
&#xD;
               -  Non-fasting glucose &lt; 125 mg/dL without the use of antihyperglycemic agents&#xD;
&#xD;
               -  If non-fasting glucose &gt; 125 mg/dL, a fasting glucose should be done. If fasting&#xD;
                  glucose =&lt; 160 mg/dL without the use of antihyperglycemic agents, participants&#xD;
                  will meet adequate metabolic function criteria&#xD;
&#xD;
               -  No history of congestive heart failure or family history of long QT syndrome.&#xD;
                  Participants who are at risk because of underlying cardiovascular disease or&#xD;
                  exposure to cardiotoxic drugs must have adequate cardiac function.&#xD;
&#xD;
               -  QTC &lt; 470 msec.&#xD;
&#xD;
               -  Shortening fraction of &gt;= 27% by echocardiogram (echocardiogram (ECHO) to be done&#xD;
                  only if history of abnormal cardiac function or abnormal electrocardiogram [EKG]&#xD;
                  at baseline. Abnormal EKGs should be discussed with the study chairs).&#xD;
&#xD;
               -  Participants with seizure disorder may be enrolled if seizure disorder is well&#xD;
                  controlled&#xD;
&#xD;
               -  The effects of the study drugs on the developing human fetus are unknown. For&#xD;
                  this reason, females of child-bearing potential and males must agree to use&#xD;
                  adequate contraception. Adequate methods include: hormonal or barrier method of&#xD;
                  birth control; or abstinence prior to study entry and for the duration of study&#xD;
                  participation. Should a woman become pregnant or suspect she is pregnant while&#xD;
                  she or her partner is participating in this study, she should inform her treating&#xD;
                  physician immediately. Males treated or enrolled on this protocol must also agree&#xD;
                  to use adequate contraception prior to the study and for the duration of study&#xD;
                  participation.&#xD;
&#xD;
               -  Karnofsky &gt;= 50 for participants &gt; 16 years of age and Lansky &gt;= 50 for&#xD;
                  participants =&lt; 16 years of age. Participants who are unable to walk because of&#xD;
                  paralysis, but who are up in a wheelchair, will be considered ambulatory for the&#xD;
                  purpose of assessing the performance score.&#xD;
&#xD;
               -  Subjects must be willing to provide archival formalin-fixed embedded (FFPE) and&#xD;
                  frozen tissue specimens for biomarker studies, if available.&#xD;
&#xD;
               -  A legal parent/guardian or participant must be able to understand, and willing to&#xD;
                  sign, a written informed consent and assent document, as appropriate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  COHORT 1A AND 1B: Prior exposure to radiation therapy.&#xD;
&#xD;
          -  COHORT 1A AND 2A: Deemed not appropriate for tissue resection/biopsy.&#xD;
&#xD;
          -  COHORT 3A AND 3B: Prior exposure to re-irradiation for tumor progression.&#xD;
&#xD;
          -  Diagnosis of a histone H3 wildtype grade II diffuse astrocytoma&#xD;
&#xD;
          -  Participants who are currently receiving another investigational drug. Investigational&#xD;
             imaging agents or agents used to enhance tumor visibility on imaging or during tumor&#xD;
             biopsy/resection should be discussed with the study chairs.&#xD;
&#xD;
          -  Participants who are currently receiving other anti-cancer agents&#xD;
&#xD;
          -  Participants with a known disorder that affects their immune system, such as human&#xD;
             immunodeficiency virus (HIV) or hepatitis B or C, or an auto-immune disorder requiring&#xD;
             systemic cytotoxic or immunosuppressive therapy. Note: Participants that are currently&#xD;
             using inhaled, intranasal, ocular, topical or other non-oral or non-intravenous (IV)&#xD;
             steroids are not necessarily excluded from the study but need to be discussed with the&#xD;
             study chair.&#xD;
&#xD;
          -  Participants with uncontrolled infection&#xD;
&#xD;
          -  Participants with history of congestive heart failure are at risk because of&#xD;
             underlying cardiovascular disease or exposure to cardiotoxic drugs must have adequate&#xD;
             cardiac function. Electrocardiogram (ECG) must be obtained as and verify the&#xD;
             following. If an abnormal reading is obtained, the ECG must be repeated in triplicate.&#xD;
&#xD;
               -  QTC &lt; 470 msec;&#xD;
&#xD;
               -  Shortening fraction of &gt;= 27% by echocardiogram&#xD;
&#xD;
          -  Female participants of childbearing potential must not be pregnant or breast-feeding.&#xD;
             Female participants of childbearing potential must have a negative serum or urine&#xD;
             pregnancy test prior to the start of therapy (as clinically indicated).&#xD;
&#xD;
          -  Active illicit drug use or diagnosis of alcoholism&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition as the agents used in study&#xD;
&#xD;
          -  Evidence of disseminated disease, including diffuse leptomeningeal disease or evidence&#xD;
             of CSF dissemination&#xD;
&#xD;
          -  Known additional malignancy that is progressing or requires active treatment within 3&#xD;
             years of start of study drug&#xD;
&#xD;
          -  Concomitant use of potent CYP3A4/5 inhibitors during the treatment phase of the study&#xD;
             and within 72 hours prior to starting study drug administration.&#xD;
&#xD;
          -  Concomitant use of potent CYP3A4/5 inducers, which include enzyme inducing&#xD;
             antiepileptic drugs (EIAEDs), during the treatment phase of the study and within 2&#xD;
             weeks prior to starting treatment. Concurrent corticosteroids is allowed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabine Mueller, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kelly Hitchner</last_name>
    <phone>(415) 502-1600</phone>
    <email>Kelly.Hitchner@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Hitchner</last_name>
      <phone>415-502-1600</phone>
      <email>Kelly.Hitchner@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>PNOC_Regulatory@ucsf.edu</last_name>
    </contact_backup>
    <investigator>
      <last_name>Sabine Mueller, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Sabine Mueller, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Diffuse Intrinsic Pontine Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panobinostat</mesh_term>
    <mesh_term>TIC10 compound</mesh_term>
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Histone Deacetylase Inhibitors</mesh_term>
    <mesh_term>GDC-0084</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data after de-identification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

